Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of "Moderate Buy" by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $6.29.

A number of brokerages recently weighed in on FULC. Piper Sandler reaffirmed an "overweight" rating and issued a $9.00 price target (up from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday, May 29th. Leerink Partnrs raised shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 23rd. HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price target on the stock in a research note on Thursday, May 15th. Finally, Leerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the company from $4.00 to $12.00 in a research note on Friday, May 23rd.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock traded down $0.07 during midday trading on Friday, reaching $6.83. The company had a trading volume of 464,290 shares, compared to its average volume of 966,867. The company has a market capitalization of $368.68 million, a P/E ratio of -22.03 and a beta of 2.41. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $10.13. The firm's fifty day simple moving average is $4.98 and its 200-day simple moving average is $4.21.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. On average, analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at about $38,000. Jump Financial LLC acquired a new stake in Fulcrum Therapeutics in the 1st quarter valued at about $30,000. Brooklyn Investment Group increased its holdings in shares of Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after buying an additional 8,254 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth approximately $39,000. Finally, Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $78,000. Institutional investors and hedge funds own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.